



US0D1033641S

(12) **United States Design Patent** (10) **Patent No.:** **US D1,033,641 S**
Morelock (45) **Date of Patent:** **** Jul. 2, 2024**

(54) **MICRONEEDLE ARRAY SENSOR APPLICATOR DEVICE**

8,094,009 B2 1/2012 Allen et al.
8,125,331 B2 2/2012 Allen et al.
8,130,095 B2 3/2012 Allen et al.
8,175,673 B2 5/2012 Say et al.

(71) Applicant: **Biolinq Incorporated**, San Diego, CA (US)

(Continued)

(72) Inventor: **David Michael Morelock**, Escondido, CA (US)

FOREIGN PATENT DOCUMENTS

AU 2015227515 B2 5/2017
EP 2 532 305 A1 12/2012

(73) Assignee: **Biolinq Incorporated**, San Diego, CA (US)

(Continued)

(**) Term: **15 Years**

OTHER PUBLICATIONS

(21) Appl. No.: **29/819,952**

Freestyle Libre 3 Sensor, usmeddirect.com, [online], [site visited Sep. 21, 2023], Available from internet, URL: <https://www.usmeddirect.com/products/freestyle-libre-3-sensor-prescription-required> (Year: 2023).*

(22) Filed: **Dec. 17, 2021**

(51) **LOC (14) Cl.** **24-02**

(Continued)

(52) **U.S. Cl.**

USPC **D24/146**

(58) **Field of Classification Search**

USPC D24/107, 108, 112, 130, 133, 146, 147, D24/186; D15/72, 78; D28/7; D9/772, D9/773, 774, 777

CPC A61M 37/0015; A61M 2037/0038; A61M 2037/0053; A61M 2037/003; A61M 2037/0023; A61M 2037/0061; A61M 2207/00; A61M 2037/0046; A61M 1/328; A61B 5/145; A61B 5/14503

See application file for complete search history.

Primary Examiner — Samantha Q Lawrence

Assistant Examiner — Thanh Luu Wong

(74) *Attorney, Agent, or Firm* — Cooley LLP

(57) **CLAIM**

The ornamental design for a microneedle array sensor applicator device, as shown and described.

DESCRIPTION

FIG. 1 is a front perspective view of a microneedle array sensor applicator device showing the new design; FIG. 2 is a front view thereof; FIG. 3 is a right side view thereof; FIG. 4 is a rear view thereof; FIG. 5 is a left side view thereof; FIG. 6 is a top plan view thereof; and, FIG. 7 is a bottom plan view thereof.


The broken lines illustrate portions of the microneedle array sensor applicator device that form no part of the claimed design.

1 Claim, 7 Drawing Sheets

(56) **References Cited**

U.S. PATENT DOCUMENTS

D178,118 S * 6/1956 Enos D15/72
D315,914 S * 4/1991 Chen D15/78
D438,794 S * 3/2001 Miles D9/425
D444,594 S * 7/2001 Angeletta D28/7
6,855,131 B2 2/2005 Trautman et al.
7,097,631 B2 8/2006 Trautman et al.
D544,298 S * 6/2007 Eide D7/565
7,582,059 B2 9/2009 Funderburk et al.
7,946,984 B2 5/2011 Brister et al.



(56)

References Cited

U.S. PATENT DOCUMENTS

			D988,160 S *	6/2023	Morelock	D24/186
			11,672,965 B2	6/2023	Mansfield et al.	
			D996,999 S *	8/2023	Morelock	D24/186
			D997,362 S *	8/2023	Donnay	A61B 5/15194
						D24/169
			D999,913 S *	9/2023	Rao	D24/186
			D1,006,235 S *	11/2023	Rao	D24/186
			D1,008,021 S *	12/2023	Jensen	D24/130
			2002/0087182 A1	7/2002	Trautman et al.	
			2004/0236251 A1*	11/2004	Roe	A61B 5/150022
						600/583
			2005/0096586 A1	5/2005	Trautman et al.	
			2005/0283114 A1*	12/2005	Bresina	A61M 5/158
						604/93.01
			2008/0114280 A1	5/2008	Stafford	
			2008/0183144 A1	7/2008	Trautman et al.	
			2008/0242961 A1	10/2008	Brister et al.	
			2010/0056873 A1	3/2010	Allen et al.	
			2011/0082484 A1	4/2011	Saravia et al.	
			2011/0106126 A1	5/2011	Love et al.	
			2011/0190603 A1	8/2011	Stafford	
			2011/0191044 A1*	8/2011	Stafford	C12Q 1/006
						702/65
			2011/0319729 A1	12/2011	Donnay et al.	
			2012/0123387 A1	5/2012	Gonzalez et al.	
			2012/0197222 A1	8/2012	Donnay et al.	
			2012/0303043 A1*	11/2012	Donnay	A61B 5/6849
						606/129
			2014/0275907 A1	9/2014	Feldman et al.	
			2014/0330209 A1	11/2014	Frederickson et al.	
			2014/0336487 A1	11/2014	Wang et al.	
			2015/0173661 A1	6/2015	Myles	
			2015/0351674 A1	12/2015	Thomas et al.	
			2016/0029931 A1	2/2016	Salas-Boni et al.	
			2017/0361079 A1	12/2017	Trautman et al.	
			2018/0317820 A1	11/2018	Pace et al.	
			2019/0059796 A1	2/2019	Larson et al.	
			2019/0120785 A1	4/2019	Halac et al.	
			2019/0125223 A1	5/2019	Wang et al.	
			2019/0133501 A1	5/2019	Rao et al.	
			2019/0133510 A1	5/2019	El Kaliouby et al.	
			2019/0239825 A1	8/2019	Kumar et al.	
			2019/0309433 A1	10/2019	Sattayasamitsathit et al.	
			2019/0336053 A1	11/2019	Halac et al.	
			2019/0339224 A1	11/2019	Bhavaraju et al.	
			2020/0037939 A1	2/2020	Castagna et al.	
			2020/0085341 A1	3/2020	Windmiller	
			2020/0101286 A1	4/2020	Windmiller et al.	
			2020/0138346 A1	5/2020	Brister et al.	
			2020/0178853 A1	6/2020	Pushpala et al.	
			2020/0209179 A1	7/2020	Bohm et al.	
			2020/0214566 A1	7/2020	Allen et al.	
			2020/0254240 A1	8/2020	Windmiller et al.	
			2020/0297997 A1	9/2020	Windmiller et al.	
			2020/0330010 A1	10/2020	Barry et al.	
			2020/0375455 A1	12/2020	Van Tassel et al.	
			2021/0000399 A1	1/2021	Curry et al.	
			2021/0007651 A1	1/2021	Donnay et al.	
			2021/0038131 A1	2/2021	Li et al.	
			2021/0076987 A1	3/2021	Stafford	
			2021/0133126 A1	5/2021	Yamakita et al.	
			2021/0142912 A1	5/2021	Belliveau et al.	
			2021/0186425 A1	6/2021	Rodriguez et al.	
			2021/0187286 A1	6/2021	Windmiller et al.	
			2021/0196162 A1	7/2021	Halac et al.	
			2021/0204841 A1	7/2021	Thomas et al.	
			2021/0219877 A1	7/2021	Baker et al.	
			2021/0236057 A1	8/2021	Pushpala et al.	
			2021/0260257 A1	8/2021	McCanless et al.	
			2021/0308009 A1	10/2021	Cho et al.	
			2021/0315493 A1	10/2021	Pace et al.	
			2021/0321914 A1	10/2021	Brister et al.	
			2021/0321942 A1	10/2021	Pushpala et al.	
			2021/0379370 A1	12/2021	Windmiller	
			2021/0393201 A1	12/2021	Morelock et al.	
			2022/0031209 A1	2/2022	Windmiller et al.	
			2022/0031244 A1	2/2022	Windmiller et al.	
			2022/0079481 A1	3/2022	Pushpala et al.	
			2022/0080678 A1	3/2022	Cole et al.	
8,252,229 B2	8/2012	Thomas et al.				
8,267,889 B2	9/2012	Cantor et al.				
8,280,475 B2	10/2012	Brister et al.				
8,284,046 B2	10/2012	Allen et al.				
D681,877 S *	5/2013	Curry	D28/7			
8,579,862 B2	11/2013	Kobayashi et al.				
8,652,043 B2	2/2014	Drucker et al.				
8,753,318 B2	6/2014	Trautman et al.				
8,758,298 B2	6/2014	Cantor et al.				
8,764,657 B2	7/2014	Curry et al.				
8,821,446 B2	9/2014	Trautman et al.				
D717,100 S *	11/2014	Moser	D7/354			
9,008,745 B2	4/2015	Pushpala et al.				
9,055,901 B2	6/2015	Brister et al.				
9,101,305 B2	8/2015	Larson et al.				
9,119,945 B2	9/2015	Simons et al.				
9,174,035 B2	11/2015	Ringsred et al.				
9,215,992 B2	12/2015	Donnay et al.				
9,357,951 B2	6/2016	Simpson et al.				
9,402,544 B2	8/2016	Yee et al.				
9,402,570 B2	8/2016	Pace et al.				
9,415,198 B2	8/2016	McAllister				
9,492,647 B2	11/2016	Stumber et al.				
9,610,401 B2	4/2017	Antonio et al.				
9,615,779 B2	4/2017	Pryor et al.				
9,636,060 B2	5/2017	Feldman et al.				
9,642,568 B2	5/2017	Shah et al.				
9,687,640 B2	6/2017	Trautman et al.				
9,717,843 B2	8/2017	Grucela et al.				
9,737,247 B2	8/2017	Wang et al.				
9,743,870 B2	8/2017	Wang et al.				
9,782,574 B2	10/2017	Simmers				
9,789,249 B2	10/2017	Frederickson et al.				
9,814,414 B2	11/2017	Brister et al.				
D806,254 S *	12/2017	Im	D24/186			
9,844,328 B2	12/2017	Simpson et al.				
9,933,387 B1	4/2018	McCanna et al.				
9,949,642 B2	4/2018	Love et al.				
9,968,742 B2	5/2018	Van Antwerp et al.				
10,010,280 B2	7/2018	Donnay et al.				
10,010,707 B2	7/2018	Colburn et al.				
D827,682 S *	9/2018	Anderson	15/78			
10,092,207 B1	10/2018	Windmiller				
10,136,846 B2	11/2018	Wang et al.				
10,213,139 B2	2/2019	Rao et al.				
10,213,141 B2	2/2019	Cole et al.				
10,278,732 B2	5/2019	Schoonmaker et al.				
10,300,260 B2	5/2019	Wirtanen et al.				
10,406,339 B2	9/2019	Simmers				
10,413,183 B2	9/2019	Antonio et al.				
10,492,685 B2	12/2019	Bernstein et al.				
10,492,708 B1	12/2019	Windmiller				
D875,254 S	2/2020	Cooke et al.				
10,595,754 B2	3/2020	Pushpala et al.				
10,596,295 B2	3/2020	Larson et al.				
10,674,944 B2	6/2020	Pace				
10,709,834 B2	7/2020	Chiu et al.				
10,863,944 B2	12/2020	Gray et al.				
10,898,115 B2	1/2021	Halac et al.				
10,932,699 B2	3/2021	Lin et al.				
10,973,443 B2	4/2021	Funderburk et al.				
10,993,646 B2	5/2021	Scott et al.				
11,045,142 B1	6/2021	Windmiller et al.				
D924,406 S *	7/2021	Yee	D24/186			
11,058,329 B2	7/2021	Simpson et al.				
11,071,478 B2	7/2021	Rao et al.				
D928,119 S *	8/2021	Walter	D14/216			
11,122,043 B2	9/2021	Love et al.				
11,172,851 B2	11/2021	Pushpala et al.				
11,357,430 B2	6/2022	Pushpala et al.				
11,406,818 B2	8/2022	Windmiller				
11,517,222 B2	12/2022	Pushpala et al.				
D980,986 S *	3/2023	Rao	A61B 5/14503			
			D24/186			
11,654,270 B2	5/2023	Mansfield et al.				

(56)

References Cited

U.S. PATENT DOCUMENTS

2022/0087610	A1	3/2022	Pushpala et al.
2022/0125344	A1	4/2022	Pushpala et al.
2022/0151516	A1	5/2022	Wang et al.
2022/0175278	A1	6/2022	Campbell et al.
2022/0370011	A1	11/2022	Windmiller et al.
2023/0033467	A1	2/2023	Pushpala et al.
2023/0074798	A1	3/2023	Tangney
2023/0094419	A1	3/2023	Mansfield, III et al.
2023/0099617	A1	3/2023	Mansfield, III et al.
2023/0137258	A1	5/2023	Windmiller
2023/0190147	A1	6/2023	Campbell et al.
2023/0256220	A1	8/2023	Mansfield, III et al.
2023/0301552	A1	9/2023	Mallires et al.
2023/0310823	A1	10/2023	Mansfield, III et al.

FOREIGN PATENT DOCUMENTS

JP	D1707722	*	2/2022
WO	WO-2007/097754	A1	8/2007
WO	WO-2013/066854	A1	5/2013
WO	WO-2014/055456	A1	4/2014
WO	WO-2018/071265	A1	4/2018
WO	WO-2019/084023	A1	5/2019
WO	WO-2019/236859	A1	12/2019
WO	WO-2019/236876	A1	12/2019
WO	WO-2020/231405	A1	11/2020
WO	WO-2021/101857	A1	5/2021
WO	WO-2021/158372	A1	8/2021
WO	WO-2021/257624	A1	12/2021
WO	WO-2023/055755	A1	4/2023
WO	WO-2023/064877	A1	4/2023
WO	WO-2023/133468	A1	7/2023

OTHER PUBLICATIONS

Dexcom G7 Sensor, pharmalynk.com, [online], [site visited Sep. 21, 2023]. Available from internet, URL: <https://store.pharmalynk.com/products/dexcom-g7-cgm> (Year: 2023).*

Abbot press release (2020). “New late-breaking data show use of Abbott’s Freestyle® Libre System significantly reduces HBA1C levels in people with type 2 diabetes using insulin or not,” 3 pages.

American Diabetes Association® Press Release (2020). “American Diabetes Association® Applauds policymakers’ Focus on Addressing High Costs of Insulin for Seven Million Americans,” 4 pages.

Bantle, J.P. et al. (1997). “Glucose measurement in patients with diabetes mellitus with dermal interstitial fluid,” *J. Lab. Clin. Med.* 130:436-441.

Beckles, G.L. et al. (2016). “Disparities in the prevalence of diagnosed diabetes—United States, 1999-2002 and 2011-2014,” *MMWR* 65:1265-1269.

Cao, J. et al. (2017). “Validation of capillary blood analysis and capillary testing mode on the epoc Point of Care system,” *Pract. Lab. Med.* 9:24-27.

Castle, J.R. et al. (2012). “The accuracy benefit of multiple amperometric glucose sensors in people with type 1 diabetes,” *Diabetes Care* 35:706-710.

Dexcom (2020). Analyst Day Presentation, 19 total pages.

Dexcom (2020). Analyst Day Presentation, 27 total pages.

Diabetes Care (2021). “7. Diabetes Technology: Standards of Medical Care in Diabetes—2021,” *Diabetes Care* 44(Supplement 1):S85-S99.

Fang, M. et al. (2021). “Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018,” *N. Engl. Med.* 384:2219-2228.

French, D.P. et al. (2008). “Original Article: Psychological Care Self-monitoring of blood glucose changed non-insulin-treated Type 2 diabetes patients’ beliefs about diabetes and self-monitoring in a randomized trial,” *Diab. Med.* 25:1218-1228.

Grady, M. et al. (2017). “Examining the Impact of a Novel Blood Glucose Monitor with Color Range indicator on Decision-Making

in Patients With Type 1 and Type 2 Diabetes and its Association With Patient Numeracy Level,” *JMIR Diabetes* 2:e24.

Grady, M. et al. (2018). “Use of Blood Glucose Meters Featuring Color Range Indicators Improves Glycemic Control in Patients with Diabetes in Comparison to Blood Glucose Meters Without Color (ACCENTS Study),” *J. Diab. Sci. Tech.* 12:1211-1219.

Groenendaal, W. et al. (2008). “Modeling Glucose and Water Dynamics in Human Skin,” *Diab. Tech. Therap.* 10:283-293.

International Search Report mailed on Sep. 9, 2021, for PCT Application No. PCT/US2021/037511, filed on Jun. 15, 2021, 2 pages.

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2008). “Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes,” *N. Engl. Med.* 359:1464-1476.

Karter, A.J. et al. (2021). “Association of Real-time Continuous Glucose Monitoring with Glycemic Control and Acute Metabolic Events Among Patients with Insulin-Treated Diabetes,” *JAMA* 325:2273-2284.

Martens, T. et al. (2021). “Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin a Randomized Clinical Trial,” *JAMA* 325:2262-2272.

McClatchey, P.M. et al. (2019). “Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays,” *Diabetes* 68:1892-1901.

Neerken, S. et al. (2004). “Characterization of age-related effects in human skin: A comparative study that applies confocal laser scanning microscopy and optical coherence tomography,” *J. Biomed. Optics* 9:274-281.

Polonsky, W.H. et al. (2011). “A survey of blood glucose monitoring in patients with type 2 diabetes: Are recommendations from health care professionals being followed?” *Curr. Med. Res. & Opinion* 27:31-37.

Rigla, M. et al. (2018). “Human Subcutaneous Tissue Response to Glucose Sensors: Macrophages Accumulation Impact on Sensor Accuracy,” *Diabetes Technology & Therapeutics* 20:296-302.

Sheikh, Z. et al. (2015). “Macrophages, Foreign Body Giant Cells and Their Response to Implantable Biomaterials,” *Materials* 8:5671-5701.

Shi, T. et al. (2016). “Modeling and Measurement of Correlation between Blood and Interstitial Glucose Changes,” *J. Diab. Res.* vol. 2016, 9 pages.

Written Opinion of the International Searching Authority mailed on Sep. 9, 2021, for PCT Application No. PCT/US2021/037511, filed on Jun. 15, 2021, 6 pages.

Al Hayek et al., “Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study” *Cureus* Oct. 27, 2020; 12(10):e11195. doi: 10.7759/cureus.11195.

Allen et al., “Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial” *Diabetes Res Clin Pract.* (2008) Jun. 80(3): 371-379. doi:10.1016/j.diabres.2008.01.006.

Barrett et al., “Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years—United States, Mar. 1, 2020-Jun. 28, 2021” *MMWR Morb Mortal Wkly Rep.* Jan. 14, 2022; 71(2):59-65. doi: 10.15585/mmwr.mm7102e2.

Centers for Disease Control, “National Diabetes Statistics Report 2020 Estimates of Diabetes and Its Burden in the United States” (2020) 32 pages.

Dunkin et al., “Scarring occurs at a critical depth of skin injury: precise measurement in a graduated dermal scratch in human volunteers” *Plast Reconstr Surg.* May 2007; 119(6):1722-1732. doi: 10.1097/01.prs.0000258829.07399.f0.

Ehrhardt et al., “Behavior Modification in Prediabetes and Diabetes: Potential Use of Real-Time Continuous Glucose Monitoring” *Journal of Diabetes Science and Technology* Mar. 2019; 13(2):271-275.

Ehrhardt et al., “The Effect of Real-Time Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Mellitus” *Journal of Diabetes Science and Technology* May 2011; 5(3):668-675.

(56)

References Cited

OTHER PUBLICATIONS

Ehrhardt et al., "Continuous Glucose Monitoring as a Behavior Modification Tool" *Clin Diabetes*. Apr. 2020;38(2):126-131. doi: 10.2337/cd19-0037.

Fonda et al., "The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes" *Journal of Diabetes Science and Technology* (2016) 10(4):898-904.

Han et al., "The End of the Road for the YSI 2300 Analyzer: Where Do We Go Now?" *Journal of Diabetes Science and Technology* (2020) 14(3):595-600.

Han et al., "The YSI 2300 Analyzer Replacement Meeting Report" *Journal of Diabetes Science and Technology* (2020) 14(3):679-686.

International Search Report and Written Opinion mailed on Mar. 20, 2023, for PCT Application No. PCT/US2022/044950, filed on Sep. 27, 2022, 26 pages.

International Search Report and Written Opinion mailed on May 22, 2023, for PCT Application No. PCT/US2023/060177, filed on Jan. 5, 2023, 20 pages.

Invitation to Pay Additional Fees mailed on Jan. 26, 2023, for PCT Application No. PCT/US2022/044950, filed on Sep. 27, 2022, 22 pages.

Invitation to Pay Additional Fees mailed on Mar. 28, 2023, for PCT Application No. PCT/US2023/060177, filed on Jan. 5, 2023, 15 pages.

Non-Final Office Action mailed on Apr. 25, 2023, for U.S. Appl. No. 17/348,651, filed Jun. 15, 2021, 24 pages.

Non-Final Office Action mailed on Dec. 7, 2022, for U.S. Appl. No. 17/954,289, filed Sep. 27, 2022, 7 pages.

Non-Final Office Action mailed on Sep. 8, 2023, for U.S. Appl. No. 18/139,308, filed Apr. 25, 2023, 7 pages.

Notice of Allowance mailed on Jan. 26, 2023, for U.S. Appl. No. 17/954,289, filed Sep. 27, 2022, 9 pages.

Notice of Allowance mailed on Jan. 3, 2023, for U.S. Appl. No. 17/954,293, filed Sep. 27, 2022, 8 pages.

Notice of Allowance mailed on Sep. 12, 2023, for U.S. Appl. No. 18/139,302, filed Apr. 25, 2023, 8 pages.

Sharifi et al., "Redundancy in Glucose Sensing: Enhanced Accuracy and Reliability of an Electrochemical Redundant Sensor for Continuous Glucose Monitoring" *Journal of Diabetes Science and Technology* (2016) 10(3):669-678.

Turner et al., "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" *The Lancet* Sep. 1998; 352(9131):837-853.

Vigersky et al., "Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients with Type 2 Diabetes" *Diabetes Care* Jan. 2012; 35:32-38.

Wolicki et al., "Epidemiology and Prevention of Vaccine-Preventable Diseases: Chapter 6: Vaccine Administration" *Centers for Disease Control and Prevention* (2021) 17 pages.

World Health Organization, "Diabetes", Sep. 16, 2022, 5 pages.

Written Opinion (Second Opinion) of the International Preliminary Examining Authority mailed on May 25, 2023, for PCT Application No. PCT/US2022/044950, filed on Sep. 27, 2022, 14 pages.

Young et al., "Glucose Self-monitoring in Non-Insulin-Treated Patients with Type 2 Diabetes in Primary Care Settings: A Randomized Trial" *JAMA Intern Med.* Jul. 2017; 177(7):920-929.

* cited by examiner




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7